Tobias Walbert

33PUBLICATIONS
200CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Epigenetics (incl. genome methylation and epigenomics)Molecular targetsBiological adaptation
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|Jul 10, 2026
Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial.

|Jul 03, 2026
Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial.

|Jun 22, 2026
Single-nucleus multiomics unveils malignant cellular states, regulatory architectures and microenvironmental reorganization across the G-CIMP epigenomic transition in IDH-mutant glioma.

|Apr 24, 2026
Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial.

|Apr 22, 2026
CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomas.

|Apr 14, 2026
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Patrick Y Wen, Donald A Berry, Meredith B Buxton

Pageof 6

Frequent Collaborators

5 joint publications

Patrick Y Wen

4 joint publications

Caroline Hertler

4 joint publications

Howard Colman

4 joint publications

Louis B Nabors